Senescence-Targeted Therapeutics

Biotechnology / Functional immune-cell selection

Senescence-Targeted Therapeutics

Two patent-pending technologies address distinct questions in identifying and qualifying selective immune-cell populations for senescence-targeted therapeutic development.

Technology 1

Identifying Selective Immune Cells

Issue: Which cytotoxic immune cells can eliminate senescent cells while limiting damage to corresponding non-senescent cells?

The first technology is designed to identify useful immune-cell populations based on their measured ability to distinguish between senescent cells and corresponding non-senescent cells through functional killing tests.

Activity against senescent targets is assessed alongside activity against non-senescent controls. The approach therefore evaluates the cells’ observed functional selectivity, rather than relying solely on predetermined senescence markers.

These measurements provide an experimental basis for identifying candidate immune-cell populations that preferentially eliminate senescent cells while limiting damage to corresponding non-senescent cells.

Technology 2

Selecting Immune Cells for a Particular Recipient

Issue: Which candidate immune-cell population demonstrates the required selectivity for this particular recipient?

The second technology is designed to evaluate candidate immune-cell populations against matched senescent and non-senescent target cells derived from the intended recipient.

Comparing the candidate’s activity against these matched targets provides a recipient-specific basis for assessing selectivity. The results support qualifying or selecting a candidate population for that individual.

The first technology asks which immune cells demonstrate selective killing of senescent cells. The second asks which candidate demonstrates the required selectivity for a particular recipient.

Research & development

Further Evaluation

The proposed applications include age-related diseases and other conditions associated with cellular senescence. Both technologies require further research and validation.

Contact:
Arthur Ruppin

arthur@gen-inno.com

+1 609 510 3746

© 2026 General Innovations, LLC

Intellectual property. Commercial potential.